PubMed Health⌕ Search

PubMed · 14647556

Primary hyperparathyroidism.

Abstract

OBJECTIVE: The aim of the study is to present the clinical pattern, surgical indication and management of primary hyperparathyroidism in a teaching hospital in the Kingdom of Saudi Arabia (KSA). METHODS: The records of patients who underwent surgical treatment for primary hyperparathyroidism at the King Khalid University Hospital, Riyadh, KSA from March 1992 to October 2002 were reviewed for epidemiological data, biochemical, radiological investigation, operative procedures, histopathology result, preoperative localization studies included neck ultrasonogram, neck computerized tomography and thallium-technetium subtraction scan. All patients underwent surgery under general anesthesia and procedures were bilateral, unilateral neck exploration, or minimal invasive parathyroidectomy. RESULTS: A total of 41 patients with diagnosis of primary hyperparathyroidism were reviewed. There were 30 females and 11 males with a mean age of 42 years (range 14-78 years). The musculoskeletal symptoms were the major symptoms in 30 patients (73%) followed by renal stone in 6 patients (14.6%), peptic ulcer in 2, acute pancreatitis in one, asymptomatic patients accounted for 5% (2 patients) and the thallium-technetium scan has the highest sensitivity rate (89%) among the preoperative localization studies. The histopathological results showed adenoma in 36 cases (87.8%), hyperplasia in 3 cases (7.3%) and no pathology found in 2 cases. CONCLUSION: Almost all the patients presented with late symptoms and complications of primary hyperparathyroidism, the number of asymptomatic patients, is low due to lack of routine serum calcium check up. Owing to the high sensitivity of thallium-technetium scan and the relatively low incidence of hyperplasia (7.3%), we believe that unilateral neck exploration guided by preoperative scan is a suitable procedure for primary hyperparathyroidism.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hayan A Bismar, Abdelkarim A El-Bakry. 2003. Primary hyperparathyroidism.. https://pubmed.ncbi.nlm.nih.gov/14647556/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas.

The high mobility group As (HMGAs) belong to a family of nonhistone nuclear proteins that orchestrate the assembly of nucleoprotein complexes. Through a complex network of protein-DNA and protein-protein interaction, they play important roles in gene transcription, recombination, and chromatin structure. This protein family is involved, through different mechanisms, in both benign and malignant neoplasias. We have recently reported that transgenic mice carrying the Hmga1 or Hmga2 genes under transcriptional control of the cytomegalovirus promoter develop pituitary adenomas secreting prolactin and growth hormone. We have shown that the mechanism of the HMGA2-induced pituitary adenoma is based on the increased E2F1 activity. The expression profile of mouse normal pituitary glands and adenomas induced in HMGA transgenic mice revealed an increased expression of the ccnb2 gene, coding for the cyclin B2 protein, in the neoplastic tissues compared with the normal pituitary gland. Here, we show, by electrophoretic mobility shift assay and chromatin immunoprecipitation, a direct binding of HMGA proteins to the promoter of ccnb2 gene, whereas luciferase assays showed that HMGAs are able to up-regulate ccnb2 promoter activity. Finally, we report an increased CCNB2 expression in human pituitary adenomas of different histotypes that is directly correlated with HMGA1 and HMGA2 expression. Because cyclin B2 is involved in the regulation of the cell cycle, these results taken together indicate that HMGA-induced cyclin B2 overexpression gives an important contribution to experimental and human pituitary tumorigenesis.

Adenoma↗

Parathyroid adenoma and primary CNS tumors.

Hyperparathyroidism onset at a young age is one feature in multiple endocrine neoplasia (MEN) type 1 and MEN type 2A cancer syndromes. There are several case reports of MEN Type 1-associated central nervous system (CNS) tumors. To determine if there is an association between parathyroid adenomas and CNS tumors, we used Swedish registry data to identify all individuals operated on for parathyroid adenomas between 1958-99 (n = 12,468). Follow-up for the occurrence of CNS tumors in these individuals was through linkage with the Swedish Cancer Registry. There were 70 observed cases of a CNS tumor diagnosed after a parathyroid adenoma, to be compared to 35 expected (standard incidence ratio [SIR] = 2.0; 95% confidence interval [CI] = 1.5-2.5). This increased risk was independent of duration of follow-up and was confined to meningiomas (SIR = 2.4, 95% CI = 1.7-3.4) and neurinomas (SIR = 3.4, 95% CI = 1.5-6.8). These results strongly indicate an association between these tumor forms that may be genetic, environmental (such as radiation) or a combination of both.

Adenoma↗

Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.

Parafibromin is the 531-amino-acid protein product encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal dominant hyperparathyroidism-jaw tumor familial cancer syndrome, sporadic parathyroid cancer, and a minority of families with isolated hyperparathyroidism. Parafibromin contains no identified functional domains but bears sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. This study addressed the expression and functional properties of human parafibromin. A survey of human and mouse tissues analysed with polyclonal antibodies to parafibromin showed specific immunoreactivity in adrenal and parathyroid glands, kidney, heart, and skeletal muscle. Subcellular fractionation and laser confocal microscopy of normal human parathyroid gland demonstrated expression of parafibromin in both the cytoplasmic and nuclear compartments. Parafibromin was expressed in four parathyroid adenomas but was absent from two parathyroid carcinomas. Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant implicated in parathyroid cancer and familial isolated hyperparathyroidism, inhibited cell proliferation, and blocked expression of cyclin D1, a key cell cycle regulator previously implicated in parathyroid neoplasia. These results demonstrate that human parafibromin is a nucleocytoplasmic protein with functions consistent with its postulated role as a tumor suppressor protein.

Adenoma↗